# RayzeBio, Inc.: Phase 3 study closed enrollment, 343 enrolled (GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | RayzeBio, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy |
| NCT ID | NCT05477576 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor |
| Intervention types | drug |
| Target enrollment | 343 |
| Site countries | United States, Belgium, Brazil, Canada, France, Netherlands, South Korea, Spain |
| Posted | 2022-07-28 |
| Planned start | 2022-03-24 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-05 |
| Last update posted | 2026-10-05 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 343 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05477576). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.